NIH Panel Updates COVID-19 Treatment Guidelines

May 16, 2022

The COVID-19 Treatment Guidelines Panel (the Panel) has revised the Ritonavir-Boosted Nirmatrelvir (Paxlovid) section of the Coronavirus Disease 2019 (COVID-19) Treatment Guidelines, including a new section entitled Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. This section includes 2 quick reference lists for clinicians:

• Box 1 lists examples of commonly prescribed medications that can be safely coadministered with ritonavir-boosted nirmatrelvir.
• Box 2 lists medications with clinically significant interactions with ritonavir-boosted nirmatrelvir.

In addition, the Panel updated Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints to highlight that this prioritization guidance should be used only when logistical or supply constraints limit the availability of therapies. When there are no supply or logistical constraints, therapies for the prevention or treatment of SARS-CoV-2 infection can be prescribed for any eligible individual as recommended in the Guidelines.

For more information on these updates, please see What's New in the Guidelines on the COVID-19 Treatment Guidelines website.